SCH-221510: Difference between revisions
CSV import |
CSV import |
||
| Line 35: | Line 35: | ||
[[Category:Receptor antagonists]] | [[Category:Receptor antagonists]] | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
<gallery> | |||
File:SCH-221510.svg|SCH-221510 | |||
</gallery> | |||
Latest revision as of 06:17, 3 March 2025
SCH-221510
SCH-221510 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the context of its role as a selective antagonist of the adenosine A2B receptor. This receptor is part of the adenosine receptor family, which plays a significant role in various physiological processes, including inflammation, immune response, and cardiovascular function.
Chemical Structure and Properties[edit]
SCH-221510 is a small molecule with a specific chemical structure that allows it to selectively bind to the adenosine A2B receptor. The molecular formula of SCH-221510 is C18H19N5O2, and it has a molecular weight of 337.38 g/mol. The compound is characterized by its high affinity and selectivity for the A2B receptor, distinguishing it from other adenosine receptor antagonists.
Mechanism of Action[edit]
The primary mechanism of action of SCH-221510 involves its antagonistic effects on the adenosine A2B receptor. By binding to this receptor, SCH-221510 inhibits the action of adenosine, a naturally occurring nucleoside that modulates various physiological processes. The blockade of the A2B receptor by SCH-221510 can lead to reduced inflammation and modulation of immune responses, making it a compound of interest in the treatment of inflammatory diseases.
Pharmacological Effects[edit]
Studies have shown that SCH-221510 can have several pharmacological effects, including:
- Anti-inflammatory effects: By blocking the A2B receptor, SCH-221510 can reduce the production of pro-inflammatory cytokines and chemokines, which are involved in the inflammatory response.
- Cardiovascular effects: The adenosine A2B receptor is involved in cardiovascular regulation, and antagonism by SCH-221510 may influence heart rate and blood pressure.
- Potential anti-cancer effects: Research has suggested that A2B receptor antagonists like SCH-221510 may have potential in cancer therapy by modulating tumor microenvironments and inhibiting tumor growth.
Clinical Research and Applications[edit]
While SCH-221510 has shown promise in preclinical studies, its clinical applications are still under investigation. The compound is being studied for its potential use in treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), and certain types of cancer. However, more research is needed to fully understand its efficacy and safety in humans.
Safety and Side Effects[edit]
As with any pharmacological agent, the safety profile of SCH-221510 is an important consideration. Preclinical studies have evaluated its toxicity and potential side effects, but comprehensive clinical trials are necessary to establish its safety in human populations. Potential side effects may include cardiovascular effects, gastrointestinal disturbances, and immune modulation.
Also see[edit]
| Pharmacomodulation | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
-
SCH-221510